Insulin (Rapid-Acting)

HUMALOG labeling warns that severe hypoglycemia can cause seizures or death, and that concentration or product mix-ups can cause overdose. Rapid insulin requires product-specific prescribing and monitoring; a short action profile does not make nonmedical use safe.^[2]

• This label directly addresses lispro; other rapid products need their own formulation-specific instructions.

Insulin can cause life-threatening hypoglycemia; HUMALOG labeling separately states that all insulins, including HUMALOG, can cause a shift in potassium that may lead to hypokalemia, which can cause respiratory paralysis, ventricular arrhythmia and death. HUMALOG labeling requires close medical supervision for regimen changes. Rapid- and long-acting insulin may be prescribed together; their presence alone is not a contraindicated combination.^[4]

• Insulin formulations have different action profiles; the inspected product label is HUMALOG.
• This site does not calculate insulin doses or provide a rescue regimen.

Call the local emergency number (911 in the US) for collapse, inability to breathe or unresponsiveness. For suspected poisoning, get help immediately; in the US call Poison Help at 1-800-222-1222. Do not give an unconscious person anything by mouth, and do not induce vomiting unless instructed by poison control or a health care professional.^[10][11]

• General first-aid guidance, not a complete symptom list or treatment protocol; use local emergency services outside the US.

In a double-blind, six-way glucose-clamp crossover study of 14 healthy volunteers, adding recombinant hyaluronidase to three commercial rapid-acting insulin analogues (lispro, aspart and glulisine) accelerated absorption and shortened action. These findings illustrate why insulin time-action values must identify the formulation.^[1]

• Small experimental clamp study; not a self-use guide or a duration estimate for every rapid insulin.
• Single-dose exposure in healthy volunteers, not people with diabetes; no qualified clinical review.

Somatropin can reduce insulin sensitivity. GENOTROPIN labeling states this directly and warns that antihyperglycemic drug doses, including insulin, may need adjustment; HUMALOG's own drug-interaction table separately names somatropin among agents that may decrease HUMALOG's glucose-lowering effect. This does not establish an additive hypoglycemia effect of growth hormone.^[3][4]

• The insulin records group multiple preparations; the inspected insulin label is HUMALOG (lispro).
• These passages do not test research secretagogues.
• Somatropin appears only as one named example within a long generic drug-class list in HUMALOG's table; it is not a dedicated somatropin/lispro trial.

OZEMPIC labeling warns that concomitant insulin can increase hypoglycemia risk and may require clinician-directed insulin adjustment. In SUSTAIN 5, semaglutide improved glycemic control on basal insulin; the trial pre-emptively reduced participants' insulin dose 20% at entry, and the numerical excess in hypoglycemia was not statistically conclusive.^[5][6]

• A supervised diabetes combination can have clinical benefit; this is not a blanket prohibition.
• The trial did not establish a doubling of risk, and its own protocol-mandated insulin-dose reduction at entry limits comparison to unmodified add-on use.

ZEPBOUND labeling warns of increased hypoglycemia risk when tirzepatide is used with insulin and calls for consideration of a clinician-directed insulin reduction.^[7]

• A label warning for insulin coadministration, not a separate trial of every insulin preparation.

MK-677 reduced insulin sensitivity in an older-adult trial, and somatropin labeling warns of reduced insulin sensitivity. These individual-agent findings motivate a possible glycemic concern; the combination and its magnitude were not tested.^[8][3]

• MK-677 results cannot be assigned to every GHRH or ghrelin-related peptide.
• Does not establish additive hypoglycemia with insulin.

In hemodialysis patients, intravenous insulin with glucose plus nebulized albuterol lowered potassium more than either treatment alone; the same study reports that albuterol blunted, rather than added to, insulin's glucose-lowering (hypoglycemic) effect. Application to the rapid- or long-acting insulin records is a formulation and route extrapolation.^[9]

• The inspected abstract does not identify an insulin analogue; this result cannot be presented as an exact study of lispro or glargine.
• Does not establish a quantitative clenbuterol interaction.
• This 1990 study describes a deliberate, supervised hyperkalemia treatment, not an adverse interaction; the potassium-lowering axis is distinct from the separate glucose-lowering-effect axis now also documented in HUMALOG's own label (see ix-insulin-albuterol-glycemic).

CYTOMEL labeling states that adding liothyronine (T3) therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic-agent or insulin requirements, and recommends monitoring glycemic control when liothyronine is started, changed or discontinued.^[12]

• A drug-class label warning naming “antidiabetic agent or insulin requirements” generically, not a named insulin-analogue trial.
• Does not establish a numeric hypoglycemia or hyperglycemia magnitude for this specific pair.

HUMALOG's drug-interaction table names albuterol as an example of a sympathomimetic agent that may decrease HUMALOG's blood-glucose-lowering effect, and recommends dose adjustment and increased glucose monitoring when these are coadministered.^[4]

• Albuterol is named as one example within a long generic drug-class list in the label, not an isolated albuterol trial.
• Describes a glucose-lowering-effect axis distinct from the potassium-lowering effect covered by ix-insulin-albuterol-potassium.